Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

0.0%

0 terminated out of 21 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

24%

5 trials in Phase 3/4

Results Transparency

43%

6 of 14 completed with results

Key Signals

6 with results100% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (4)
Early P 1 (1)
P 1 (1)
P 2 (7)
P 3 (4)
P 4 (1)

Trial Status

Completed14
Unknown4
Withdrawn2
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT01994109Phase 3CompletedPrimary

Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects

NCT02610868Phase 3CompletedPrimary

Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

NCT07516860Not ApplicableActive Not RecruitingPrimary

Effect of SCS Technique on Oromotor Skills in Children With CP

NCT05164367Early Phase 1Completed

Pharmacokinetics of Atropine Oral Gel

NCT05097079Phase 3WithdrawnPrimary

Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric Subjects

NCT06101160CompletedPrimary

Botulinum Toxin Injection for Sialorrhea in Cerebral Palsy

NCT04197037CompletedPrimary

Prevalence of Sialorrhea in Patients Treated With Clozapine

NCT04873115Phase 4UnknownPrimary

Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,

NCT03704168Not ApplicableWithdrawnPrimary

Safety and Efficacy of Cryoablation in Management of Sialorrhea in Patients With Neurological Disorders

NCT03747536Phase 2UnknownPrimary

Ipratropium Bromide Spray as Treatment for Sialorrhea in Children

NCT02382198Phase 2UnknownPrimary

Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease

NCT02613494Phase 1CompletedPrimary

Clozapine-induced Hypersalivation - Feasibility Trial

NCT01653132Phase 2CompletedPrimary

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

NCT01551940Phase 2CompletedPrimary

Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea

NCT02425176Phase 2CompletedPrimary

Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases

NCT01118143Not ApplicableCompleted

Oral Health Literacy Tailored Communication

NCT01191398Not ApplicableCompletedPrimary

Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation

NCT01489904Phase 2UnknownPrimary

Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy

NCT00491894Phase 3Completed

Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions

NCT00125203Phase 2Completed

Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)

Scroll to load more

Research Network

Activity Timeline